TG Therapeutics (TGTX)

Statistics

Metric	Value
Last Close	$64.51
Blended Price Target	54.74
Blended Margin of Safety	-15.1% Overvalued
Rule of 40 (Next)	42.5%
Rule of 40 (Current)	68.5%
FCF-ROIC	6.5%
Sales Growth Next Year	36.0%
Sales Growth Current Year	62.0%
Sales 3-Year Avg	67.8%
Industry	Biotechnology

Analysis

TG Therapeutics has evolved from a development-stage biotechnology company into a commercial business anchored by BRIUMVI, an anti-CD20 therapy for relapsing forms of multiple sclerosis. That transition materially improves business quality: third-quarter 2026 global revenue reached approximately $259.9 million, while U.S. BRIUMVI revenue rose about 52% year over year to $232.6 million.^[2] Management also raised its 2026 BRIUMVI U.S. revenue guidance to approximately $915–920 million, indicating continued execution rather than merely a one-time launch effect.^[2]

The revenue outlook is strong but not highly predictable in the way a subscription business is. Sales depend on physician adoption, patient starts, reimbursement, treatment persistence, and competition among multiple sclerosis therapies. TG’s moat is therefore specialized rather than broad: clinical evidence, regulatory approval, commercial relationships, and growing physician familiarity protect the product, but do not eliminate substitution risk. Leadership has demonstrated effective commercialization and capital discipline through the company’s transition to profitability-oriented operations, although durability ultimately depends on extending BRIUMVI’s lifecycle and successfully developing additional products.

What the Company Does

TG Therapeutics develops and commercializes medicines for B-cell-mediated diseases, with BRIUMVI as its principal commercial product. The company earns revenue primarily by selling BRIUMVI in the United States through the specialty pharmaceutical distribution and reimbursement system. The treatment is administered by healthcare providers, making access, infusion infrastructure, payer coverage, and neurologist adoption central to commercialization.

Recent disclosures indicate that the business is overwhelmingly concentrated in BRIUMVI. Product revenue was $235.8 million in the second quarter of 2026, including $227.7 million from U.S. BRIUMVI sales, while six-month product revenue was $437.1 million.^[10] This concentration gives the company a clear operating focus but also leaves the financial profile dependent on one commercial franchise.

Revenue Recurrence & Predictability

TG’s revenue is transactional rather than subscription-based or contractually recurring. Each sale is generated when a patient receives treatment and the company obtains reimbursement through distributors, providers, and payers. Repeat demand can be economically durable because multiple sclerosis is a chronic disease, but individual revenue is still exposed to treatment switching, discontinuation, reimbursement delays, and variability in patient starts.

The company does not disclose a percentage of revenue that is recurring or highly predictable in the recent materials available. Qualitatively, BRIUMVI revenue has greater repeat-purchase characteristics than a one-time therapy, yet it remains less predictable than recurring software or long-term contracted revenue. Quarterly visibility should improve as the treated patient base expands, but sales concentration in one product keeps forecasting sensitivity high.

Revenue Growth Durability

TG can plausibly sustain above-market growth while BRIUMVI continues penetrating the relapsing multiple sclerosis market. The main levers are new patient starts, switching from competing anti-CD20 therapies, broader neurologist adoption, improved payer access, and greater treatment persistence. Management’s approximately $1 billion 2026 total global revenue target and higher BRIUMVI guidance reflect substantial near-term momentum.^[2]

The longer-term opportunity depends on converting launch momentum into durable share gains and extending the product’s convenience profile. Positive data for single-infusion initiation and development of quarterly subcutaneous dosing could reduce administration friction; top-line Phase 3 data for the subcutaneous program were expected by year-end 2026 or early 2027.^[2] Structural headwinds include a finite addressable market, competing high-efficacy therapies, biosimilar and pricing pressure over time, and the difficulty of sustaining rapid growth from an increasingly larger base.

Economic Moat

TG’s strongest advantages are intangible assets: BRIUMVI’s regulatory approval, clinical data, manufacturing know-how, safety experience, and the commercial infrastructure required to serve neurologists and infusion centers. Seven-year efficacy and safety follow-up presented in 2026 may strengthen physician confidence and support persistence.^[2] The company’s focus on multiple sclerosis also allows its commercial organization to build disease-specific expertise.

The moat is meaningful but not impregnable. There are limited network effects, little customer switching cost for physicians, and no obvious structural cost advantage. BRIUMVI can be replaced by other approved therapies if clinical preferences, convenience, payer policies, or pricing favor competitors. The moat could widen if subcutaneous or simplified dosing improves convenience and if additional indications or products emerge; otherwise, it may narrow as competitors improve their own formulations and evidence bases.

Management & Leadership

TG is not best characterized as a founder-led company. Chief Executive Officer Michael S. Weiss has been associated with the company since its early years and has played a central role in its strategic direction and commercialization, while Chairman and Executive Chairman investment banker-turned-biotech executive Robert J. Chiascione has also been influential. The key leadership achievement is the shift from development risk to successful BRIUMVI commercialization.

Recent proxy information reported that directors and executive officers collectively owned or could acquire approximately 8.87% of outstanding shares as of April 14, 2026.^[5] That level creates meaningful alignment, though it also means governance should be monitored as the company scales. Capital allocation has emphasized commercial execution and pipeline development rather than building a diversified portfolio prematurely.

Key Risks

The largest business risk is product concentration. BRIUMVI accounts for nearly all current product revenue, so an unexpected safety signal, manufacturing disruption, reimbursement setback, or weaker-than-expected patient demand could affect the company disproportionately. Rapid growth also raises execution demands across supply, field sales, patient support, and distribution.

Competitive and regulatory risks remain substantial. Multiple sclerosis treatment is crowded, and established anti-CD20 therapies, oral medicines, infusions, and future biosimilars can compete on efficacy, convenience, safety, and price. The subcutaneous program may improve BRIUMVI’s positioning, but it still requires successful clinical development and regulatory approval; the company cannot assume that a more convenient formulation will translate into superior commercial adoption.

Finally, pipeline expansion introduces clinical and operational uncertainty. TG must fund research, manage trials, and allocate resources without diluting attention from its core franchise. Recent institutional filings also show significant ownership by large investors, while insider ownership is material; neither changes the underlying requirement for management to preserve execution quality as the business becomes more dependent on one major product.^[1][5]

---

Sources

1. https://www.sec.gov/Archives/edgar/data/0001001316/000210012126000832/xslSCHEDULE13GX02/primary_doc.xml
2. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-third-quarter-2026-financial-results-and
3. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001001316/000143774926015246/tgtx20260331_10q.htm
4. https://www.sec.gov/Archives/edgar/data/1001316/000201238326003853/0002012383-26-003853-index.html
5. https://www.sec.gov/Archives/edgar/data/1001316/000143774926014233/tgtx20260301_def14a.htm
6. https://ir.tgtherapeutics.com/financial-information/quarterly-results
7. https://ir.tgtherapeutics.com/
8. https://ir.tgtherapeutics.com/sec-filings/sec-filing/4/0001437749-26-020675
9. <https://ir.tgtherapeutics.com/index.php/financial-information/sec-filings?fieldnirsecciktargetid=&fieldnirsecdatefiledvalue=&itemsperpagetoggle=1&page=26&itemsperpage=10&order=fieldnirsecdescription&sort=asc>
10. https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/ex_997107.htm